Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Table 1 Annual transition probabilities (%) for EDSS states and annual probability of relapse (%) in patients with RRMS

EDSS From\To	0-2.5	3-5.5	6-7.5	8-9.5	source	Death	Source
0-2.5	82.567	15.93	1.47	0.033	[36, 37, 38 ]	1.343	[39]
3-5.5	10.07	59.73	28.8	1.4		1.718
6-7.5	0.3	5.5	81.95	12.25		2.685
8-9.5	0	0.1	4.15	95.75		5.450
annual probability of relapse		Mean			Source
Rituximab		0.104			[40]
Natalizumab		0.265			[41]

ISSN: 1472-6963